ProCE Banner Activity

DISCOVER: More Rapid and Sustained Protective Levels of TFV-DP With FTC/TAF vs FTC/TDF as PrEP

Slideset Download
Conference Coverage

Differences in pharmacokinetics may account for the trend toward lower HIV infection rates with FTC/TAF vs FTC/TDF as PrEP in MSM and transgender women enrolled on the phase III DISCOVER trial.

Released: July 26, 2019

Share

Provided by

Provided by the USF Health
ProCE Banner

Supporters

Educational grant provided by:

Gilead

ViiV Healthcare

Partners

IAS 2018

ProCE Banner

IAS 2019

ProCE Banner